

Special Issue

Predictive and Prognostic Markers in Brain Tumors: From Physiopathology to Clinical Applications

Message from the Guest Editor

To date, brain tumors are often still life-threatening pathologies. Among these, meningiomas and glioblastoma are the most frequent histopathological types, with limited therapeutical options and heterogeneous prognosis and response to adjuvant treatments. There is a critical need to identify new prognostic and predictive markers in these tumors. In this Special Issue, the authors will focus on molecular and histopathological features of brain tumors, from physiopathological insights to clinico-pathological applications and the identification of new potential therapeutical targets. It may be based on preclinical models as well as clinical series, with various methods, such as cell culture and transfection, histology, image analysis, immunohistochemistry, PCR, transcriptomics, and methylome.

Guest Editor

Dr. Guillaume Gauchotte

Département of Biopathology - Anatomie et Cytologie Pathologiques, CHRU Nancy, Institut de Cancérologie de Lorraine Institut Médico-Légal de Nancy, 54000 Nancy, France

Deadline for manuscript submissions

closed (15 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/91902

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)